Profile data is unavailable for this security.
About the company
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
- Revenue in USD (TTM)694.96m
- Net income in USD-90.73m
- Incorporated2006
- Employees711.00
- LocationPacira Biosciences Inc5401 West Kennedy Boulevard, Suite 890TAMPA 33609United StatesUSA
- Phone+1 (813) 553-6680
- Fax+1 (302) 655-5049
- Websitehttps://www.pacira.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc | 1.13bn | -208.80m | 513.67m | 1.60k | -- | 1.01 | -- | 0.4564 | -4.10 | -4.10 | 21.19 | 9.40 | 0.6678 | 2.21 | 6.66 | 703,437.50 | -12.39 | -2.94 | -16.86 | -3.66 | 33.51 | 53.24 | -18.55 | -5.95 | 1.47 | -1.20 | 0.5658 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| SNDL Inc | 651.80m | -79.00m | 525.69m | 2.52k | -- | 0.608 | -- | 0.8065 | -0.3015 | -0.3015 | 2.48 | 3.26 | 0.6062 | 4.98 | 36.38 | 259,062.80 | -7.61 | -24.44 | -8.22 | -27.94 | 25.69 | 22.49 | -12.55 | -62.17 | 4.16 | -- | 0.114 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| ASP Isotopes Inc | 2.30m | -27.05m | 593.50m | 76.00 | -- | 39.48 | -- | 258.53 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
| CorMedix Inc | 12.26m | -46.15m | 604.35m | 82.00 | -- | 9.82 | -- | 49.29 | -0.8011 | -0.8011 | 0.212 | 1.01 | 0.1451 | -- | -- | 149,539.50 | -54.61 | -54.84 | -64.60 | -62.32 | 83.57 | 6.18 | -376.35 | -18,323.42 | 3.60 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Eyepoint Pharmaceuticals Inc | 45.71m | -103.57m | 609.46m | 121.00 | -- | 2.19 | -- | 13.33 | -2.01 | -2.01 | 0.9018 | 4.09 | 0.1983 | 1.05 | 106.19 | 377,793.40 | -44.94 | -40.44 | -59.48 | -47.79 | 91.48 | 83.45 | -226.57 | -186.23 | 5.45 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 26.27m | -339.45m | 638.64m | 452.00 | -- | -- | -- | 24.31 | -5.69 | -5.69 | 0.4398 | -2.74 | 0.0842 | 2.68 | -- | 58,119.47 | -108.79 | -83.26 | -126.95 | -93.77 | 83.54 | -- | -1,292.14 | -135,982.00 | 5.68 | -5.60 | 1.56 | -- | -- | -- | -1.96 | -- | -- | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Elite Pharmaceuticals Inc | 71.17m | -6.39m | 658.91m | 64.00 | -- | 13.94 | -- | 9.26 | -0.0059 | -0.0059 | 0.0677 | 0.0443 | 0.8957 | 2.68 | 4.46 | 1,112,051.00 | -8.04 | 19.07 | -10.06 | 24.29 | 44.73 | 46.63 | -8.98 | 20.77 | 2.42 | 0.75 | 0.1634 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| Avid Bioservices Inc | 142.36m | -144.17m | 786.66m | 371.00 | -- | 13.38 | -- | 5.53 | -2.27 | -2.27 | 2.24 | 0.9192 | 0.3661 | 3.81 | 4.32 | 383,714.30 | -37.08 | -0.826 | -57.59 | -1.20 | 6.27 | 19.26 | -101.27 | -2.14 | 1.05 | -3.18 | 0.7343 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
| Pliant Therapeutics Inc | 0.00 | -201.68m | 789.88m | 158.00 | -- | 2.28 | -- | -- | -3.34 | -3.34 | 0.00 | 5.68 | 0.00 | -- | -- | 0.00 | -40.90 | -33.24 | -43.90 | -35.39 | -- | -- | -- | -360.29 | -- | -- | 0.0802 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Evolus Inc | 248.33m | -55.46m | 797.85m | 322.00 | -- | 135.31 | -- | 3.21 | -0.9141 | -0.9141 | 4.11 | 0.0931 | 1.25 | 4.59 | 6.61 | 909,619.10 | -27.90 | -40.92 | -38.48 | -59.74 | 69.94 | 65.43 | -22.33 | -80.46 | 2.23 | -2.04 | 0.9537 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Pacira Biosciences Inc | 694.96m | -90.73m | 810.34m | 711.00 | -- | 1.08 | -- | 1.17 | -2.15 | -2.15 | 13.03 | 16.24 | 0.4548 | 1.71 | 7.03 | 977,436.00 | -5.94 | 3.35 | -6.83 | 3.98 | 74.35 | 72.63 | -13.06 | 8.57 | 1.89 | -- | 0.4393 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Liquidia Corp | 15.61m | -119.48m | 894.59m | 136.00 | -- | 8.15 | -- | 57.31 | -1.62 | -1.62 | 0.2111 | 1.31 | 0.0857 | -- | 4.14 | 114,779.40 | -65.55 | -55.02 | -75.02 | -62.69 | 64.65 | 82.18 | -765.37 | -474.59 | 6.33 | -31.14 | 0.5059 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Phibro Animal Health Corp | 1.05bn | 17.41m | 961.56m | 1.94k | 55.30 | 3.72 | 17.90 | 0.9186 | 0.4293 | 0.4293 | 25.82 | 6.38 | 1.08 | 2.60 | 6.75 | 539,568.10 | 1.80 | 3.93 | 2.20 | 4.90 | 31.47 | 31.18 | 1.66 | 3.77 | 1.69 | 2.20 | 0.6472 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| Collegium Pharmaceutical Inc | 599.25m | 88.59m | 966.22m | 197.00 | 14.98 | 4.12 | 4.08 | 1.61 | 2.00 | 2.00 | 13.05 | 7.27 | 0.4261 | 6.25 | 2.92 | 3,041,853.00 | 6.30 | 2.79 | 9.38 | 4.80 | 62.36 | 50.88 | 14.78 | 5.16 | 0.8832 | 3.94 | 0.7873 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
Data as of Nov 22 2024. Currency figures normalised to Pacira Biosciences Inc's reporting currency: US Dollar USD
62.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.95m | 15.08% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.15m | 11.17% |
| Pacer Advisors, Inc.as of 30 Sep 2024 | 4.96m | 10.76% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.01m | 4.37% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 1.98m | 4.29% |
| D. E. Shaw & Co. LPas of 30 Sep 2024 | 1.96m | 4.24% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 1.79m | 3.89% |
| DOMA Perpetual Capital Management LLCas of 30 Sep 2024 | 1.75m | 3.79% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 1.21m | 2.62% |
| Arrowstreet Capital LPas of 30 Sep 2024 | 1.15m | 2.50% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
